Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Obesity 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Inflammation 1Hodgkin Disease 1Healthy Adult Participants 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colorectal Neoplasia 1Chemotherapy Effect 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Advanced Solid Tumors 1

Interventions

Cisplatin 26Paclitaxel 21pembrolizumab 15Radiotherapy 13Carboplatin 13tislelizumab 12Fluorouracil 12Drug Therapy 11Irinotecan 9toripalimab 8Esophagectomy 8Oxaliplatin 6Nivolumab 6Capecitabine 6Neoadjuvant Therapy 5Leucovorin 5Docetaxel 5lenvatinib 4camrelizumab 4Taxes 4Radiation 4Levoleucovorin 4Immune Checkpoint Inhibitors 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4spartalizumab 3sintilimab 3apatinib 3Itraconazole 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Omeprazole × 1 year × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡